On action of 5-bromosalicylhydroxamic acid against drug resistance in tuberculosis

British Journal of Tuberculosis and Diseases of the Chest Pub Date : 1958-01-01 DOI:10.1016/S0366-0869(58)80055-6

S. Hornung , F. Amałowicz , Z. Broda , Z. Neciuk-Szczerbiński , E. Paryski , M. Polończyk , T. Rapf

{"title":"On action of 5-bromosalicylhydroxamic acid against drug resistance in tuberculosis","authors":"S. Hornung , F. Amałowicz , Z. Broda , Z. Neciuk-Szczerbiński , E. Paryski , M. Polończyk , T. Rapf","doi":"10.1016/S0366-0869(58)80055-6","DOIUrl":null,"url":null,"abstract":"<div>Two groups of patients have been treated with isonicotinic acid hydrazide (INAH) with 5-bromosalicylhydroxamic acid (T40) or p-aminosalicylic acid (PAS) for three months.One group of 119 was treated with INAH + T40, a second group of 48 was given INAH + PAS.Resistance of mycobacteria Tb towards INAH has been followed in the course of treatment.Before treatment 75 patients in the group INAH + T40 and 24 patients in the group INAH + PAS showed a full sensitivity of bacteria towards INAH.After treatment, in 40 cases (53·3 per cent.) out of 75 patients of the first group and in 14 cases (58·3 per cent.) out of 24 of the second group bacteria remain sensitive towards INAH.Both figures are essentially the same (t=0·43).The number of cases where strains of bacteria developed resistance towards INAH (at concentration 5–25 mcg./ml.) were:</div>","PeriodicalId":100202,"journal":{"name":"British Journal of Tuberculosis and Diseases of the Chest","volume":"52 1","pages":"Pages 19-25"},"PeriodicalIF":0.0000,"publicationDate":"1958-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0366-0869(58)80055-6","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Tuberculosis and Diseases of the Chest","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0366086958800556","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 5

Abstract

Two groups of patients have been treated with isonicotinic acid hydrazide (INAH) with 5-bromosalicylhydroxamic acid (T40) or p-aminosalicylic acid (PAS) for three months.

One group of 119 was treated with INAH + T40, a second group of 48 was given INAH + PAS.

Resistance of mycobacteria Tb towards INAH has been followed in the course of treatment.

Before treatment 75 patients in the group INAH + T40 and 24 patients in the group INAH + PAS showed a full sensitivity of bacteria towards INAH.

After treatment, in 40 cases (53·3 per cent.) out of 75 patients of the first group and in 14 cases (58·3 per cent.) out of 24 of the second group bacteria remain sensitive towards INAH.

Both figures are essentially the same (t=0·43).

The number of cases where strains of bacteria developed resistance towards INAH (at concentration 5–25 mcg./ml.) were:

查看原文本刊更多论文

5-溴水杨酸对结核病耐药作用的研究

两组患者分别用异烟酸肼(INAH)联合5-溴水杨基羟肟酸(T40)或对氨基水杨酸(PAS)治疗3个月。其中一组119人采用INAH + T40治疗，另一组48人采用INAH + PAS治疗。在治疗过程中已观察到结核分枝杆菌对INAH的耐药性。治疗前，INAH + T40组75例，INAH + PAS组24例，细菌对INAH完全敏感。治疗后，第一组75例患者中有40例(53.3%)细菌对INAH敏感，第二组24例患者中有14例(58.3%)细菌对INAH敏感。两个数字本质上是相同的(t=0·43)。菌株对INAH(浓度5-25微克/毫升)产生耐药性的病例数为:

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Tuberculosis and Diseases of the Chest

自引率

0.00%

发文量